Schall Law Firm Targets Phreesia in Securities Fraud Class Action

The complaint alleges that Phreesia violated the Securities Exchange Act of 1934 by issuing false and misleading statements to the market. Specifically, the firm claims the company misrepresented the stability of its Network Solutions segment, asserting that pharmaceutical marketing commitments would drive growth while ignoring underlying uncertainties that jeopardized revenue targets. When these realities surfaced, the stock value declined, causing significant losses for shareholders.

Those seeking to participate in the potential class action must contact the Schall Law Firm by July 13, 2026. Brian Schall is currently overseeing inquiries at the firm's Los Angeles office. As the class has not yet been certified, shareholders currently remain unrepresented and may choose to take independent action or remain absent members of the class until formal certification occurs.